Altria (MO): Q2 2026 results, my verdict

2026-07-30 · By Lubin Danilo, founder of Lubin Investment

MO: see the full analysis on Lubin Investment

Altria reported on July 30, 2026 adjusted earnings per share of $1.48, up 2.8% despite cigarette volumes down over 4%. My quality filter validates 9 out of 10 criteria. But the stock trades at the 95th percentile of its own price history: here is why I do not buy even a company this good at this level.

What just landed: fewer volumes, more earnings

Altria released its second-quarter 2026 results on July 30, 2026: revenue of $6.11 billion, well above expectations, and adjusted earnings per share of $1.48, up 2.8% year over year but slightly below analyst consensus. The company narrowed its full-year adjusted earnings-per-share guidance to $5.61-$5.72, growth of 3.5% to 5.5% versus $5.42 in 2025.

The volume detail shows the group's real mechanics: US cigarette shipments fell 3.2% for the quarter, and adjusted unit volume fell 4.5% year over year. This is a real decline, but it has moderated for the fourth straight quarter, helped by less switching from smokers toward untaxed illicit e-vapor products. On the next-generation side, management expects a controlled return of NJOY ACE (its e-cigarette) in the second half of 2026, once necessary regulatory and legal steps are cleared; current guidance prudently assumes this return does NOT happen in 2026.

Why my filter validates 9 out of 10 criteria

Altria checks nearly every box: a net margin of 34.3% (out of every $100 in sales, over $34 ends up as net profit, an extremely high level), cash return on capital employed (Cash ROCE) of 49.8%, cash profitability (free cash flow margin) of 36.8%, controlled debt (net debt would take just 2.44 years of free cash flow to repay), and shares outstanding down 2.23% a year thanks to sustained buybacks. The mechanism behind all of this: pricing power. A regular smoker rarely switches brands or quits abruptly because of a price increase; Altria can therefore raise prices faster than its volumes decline, which pushes earnings per share higher even as the cigarettes it sells shrink every year.

The only criterion that fails clearly is total sales growth, down 2.6% a year on average over five years, exactly the mirror image of the structural decline in US smoking. The earnings-per-share growth criterion sits in warning territory at just 5.1% a year: a decent pace but a slowing one, a sign that pricing power has limits and cannot indefinitely offset a volume shrinking every year. This is the classic melting-ice-cube profile: a company shrinking in volume whose per-share profitability holds up through price and buybacks, up to a point.

The price: at the absolute top of its recent history

Altria trades today at 13.2 times its annual free cash flow (P/FCF), a multiple sitting at the 95th percentile of its last five years: pricier than 95% of the time over that period, nearly the most expensive it has ever been over the recent cycle. My reasonable-buy-price model, projecting the five-year cash-per-share trajectory, puts the entry point at $24.72 against a current price of $67.94: a 63.6% premium, one of the widest I currently measure across my covered universe.

Why does the market pay such a level for a company whose total sales are declining? Probably because Altria is seen as a safe haven (generous dividend, massive buybacks, extreme profitability), sought after when investors want predictable cash flow. My verdict: the quality of the business model is real, but at this price, the market leaves no margin of safety if the volume decline accelerates again or if NJOY's return is delayed. This is a scarcity premium paid for predictability, not a valuation opportunity.

The real debate

The whole Altria thesis comes down to one question: can pricing power keep offsetting a volume declining year after year, indefinitely? Historically, yes, for decades. But every passing year brings the company closer to a point where price increases start accelerating smokers' departure toward cheaper or illicit alternatives too. NJOY is the bet on the next generation, but its return still hinges on regulatory steps not yet cleared.

How I settle it

I respect the quality of Altria's business model (9 out of 10 criteria, rare profitability), but I do not buy at the 95th percentile of its own price history: the margin of safety has vanished. I would wait for either a significant pullback in the price, or confirmation that NJOY returns and revives a real growth trajectory, before reconsidering. That is exactly what my stock analysis site is built to make objective: separating a quality company from a good entry price.

Altria validates 9 out of 10 criteria: 34.3% net margin, 49.8% Cash ROCE, controlled debt (2.44 years of FCF).
Earnings per share rise thanks to pricing power, despite cigarette volumes down 4.5% year over year and total sales down 2.6%/year over 5 years.
NJOY, the bet on the next generation, hinges on a controlled return in the second half of 2026, not guaranteed in current guidance.
P/FCF of 13.2x, at the 95th percentile of its own 5-year history: nearly the most expensive it has ever been, a 63.6% premium per my model.
Verdict: real quality, but a price that no longer leaves a margin of safety if the volume decline accelerates again.

FAQ

How does Altria grow earnings while cigarette sales decline?

Through pricing power: a regular smoker rarely switches brands because of a price hike. Altria raises prices faster than its volumes decline, which pushes earnings per share higher even as the cigarettes it sells shrink every year.

What is NJOY and why does it matter for the Altria thesis?

NJOY is Altria's e-cigarette brand, its bet on the next generation of nicotine products. A controlled market return is planned for the second half of 2026, subject to regulatory and legal steps not yet cleared; current guidance prudently does not assume this return.

Should you buy Altria stock after these results?

My quality filter is very favorable (9/10), but my model shows a 63.6% premium, with P/FCF at the 95th percentile of its own history. I do not see a sufficient margin of safety at this price. This is not personalized investment advice, do your own research.

What is Cash ROCE and why is Altria's so high?

Cash ROCE measures what every dollar reinvested in the business earns back in cash. At 49.8%, Altria shows an extreme level because it needs very little investment in plants or equipment to maintain sales: a capital-light model despite selling a physical product.

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).